<DOC>
	<DOC>NCT00642018</DOC>
	<brief_summary>The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.</brief_summary>
	<brief_title>A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable Hormone refractory prostate cancer defined as progressive based by documented 2 increase PSA values over a previous reference value. ECOG status 02 Adequate hematological functions, liver and renal functions Known hypersensitivity to docetaxel or taxane therapy Documented central nervous system or leptomeningeal metastasis at time of study entry Had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area. Evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary. Have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
</DOC>